Cedars-Sinai Develops AI to Predict Adverse Cardiac Events

May 2, 2023

A new Cedars-Sinai AI tool may help predict the chance of adverse cardiac events and show how a
patient’s risk for these events can change over time.

By Shania Kennedy

Cedars-Sinai researchers have developed an artificial intelligence (AI) tool that can predict a patient’s chance of adverse cardiac events, such as a heart attack, and demonstrate how that patient’s risk may change over time, according to a study published this week in npj Digital Medicine.

According to a press release detailing the study’s findings, the AI tool could help provide patients with personalized risk assessments and insights into their heart health.

“Using a specific type of AI trained to interpret images of the heart and developed at Cedars-Sinai, we could both predict the chance of cardiac events—like death, heart attack, or the need for urgent treatment of the heart vessels—and show how the likelihood of these adverse events changes over time,” explained Piotr Slomka, PhD, director of Innovation in Imaging at Cedars-Sinai and a research scientist in the Division of Artificial Intelligence in Medicine and the Smidt Heart Institute.

Read more…

Adverse reactions or quality problems experienced with the use of a recalled product can be reported to the FDA’s MedWatch Adverse Event Reporting Program online, by mail, or by fax.

Submit a Report Online:

https://www.accessdata.fda.gov/scripts/medwatch/index.cfm

Send a Report Via U.S. Mail or Fax:

Download a form from https://www.fda.gov/safety/reporting-serious-problems-fda/formsreporting-fda or call 1-800-332-1088 to request a reporting form. Then complete and return to the address on the form or submit by fax to 1-800-FDA-0178.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.

demo-attachment-261-Group-56
demo-attachment-606-Group-43
demo-attachment-1121-Rectangle-602

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager
demo-attachment-180-Group-4